Related content

Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea

By Tutaeva V.   Misurin A. V.   Michiels J. J.   Rozenberg J. M.   Sokolova M. A.   Ivanova V. L.   Kolosheinova T. I.   Manakova T. E.   Levina A. A.   Semenova E. A.   Khoroshko N. D.  

Hematology, Vol. 12, Iss. 6, 2007-12 ,pp. : 473-479

Maney Publishing

Access to resources Recommend Favorite

Different involvement of the megakaryocytic lineage by the JAK2^V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis

By Hussein Kais   Brakensiek Kai   Buesche Guntram   Buhr Thomas   Wiese Birgitt   Kreipe Hans   Bock Oliver  

Annals of Hematology, Vol. 86, Iss. 4, 2007-04 ,pp. : 245-253

Springer Publishing Company

Access to resources Recommend Favorite

Fluorescence in situ hybridization analysis of the PRV-1 gene in polycythemia vera - Implications for its role in diagnosis and pathogenesis

By Najfeld V.   Fuchs S.   Merando P.   Lezon-Geyda K.   Fruchtman S.  

Experimental Hematology, Vol. 31, Iss. 2, 2003-02 ,pp. : 118-121

Elsevier

Access to resources Recommend Favorite

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis

By Silver Richard T   Kiladjian Jean-Jacques   Hasselbalch Hans Carl  

Expert Review of Hematology, Vol. 6, Iss. 1, 2013-02 ,pp. : 49-58

Informa Healthcare

Access to resources Recommend Favorite

JAK2 46/1 haplotype is associated with JAK2 V617F – positive myeloproliferative neoplasms in Brazilian patients

By  

International Journal Of Laboratory Hematology, Vol. 37, Iss. 5, 2015-10 ,pp. : 654-660

John Wiley & Sons Inc

Access to resources Recommend Favorite